Article

Live Attenuated Flu Vaccine Is Safe for Kids with Asthma, Study Finds

Author(s):

Recommendations that children with asthma not get live attenuated flu vaccine may not be necessary, researchers found.

influenza, flu shots, infectious disease, pediatrics, primary care, hospital medicine, asthma, vaccination, vaccine

The Advisory Committee on Immunization Practices has warned physicians not to use live attenuated influenza vaccine (LAIV) on children with asthma.

Reporting at IDWeek 2016 in New Orleans, LA, Nicola Klein, MD, PhD, of the Kaiser Permanente Vaccine Study Center in Oakland, CA, and colleagues found that is likely not a necessary precaution.

They looked at whether the live vaccine caused more problems in children with asthma than inactivated vaccine.

The study subjects were children vaccinated at Kaiser network facilities from July 1, 2007 to March 31, 2014.

All were between two and 18 years old with a history of asthma.

The researchers ranked the subjects’ asthma severity with hospitalization or ED visit as the most severe.

They found that among 387,633 immunizations, 85% were with inactivated virus and 15% with LAIV. The children getting LAIV were less likely to have active persistent asthma.

Analysis of asthma exacerbations in both groups showed a decreased risk with live virus.

“Among children and adolescents with a history of asthma we found no evidence that LAIV was associated with an increased risk of asthma exacerbations regardless of severity,” they concluded.

“Concerns about administering LAIV to children with asthma may not be warranted,” they said.

According to the US Centers for Disease Control and Prevention, the live virus vaccine generally confers greater flu protection.

Several of the study researchers reported they receive funds from pharmaceutical companies.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.